Drug
Dexelvucitabine clinical trials
Also written Elvucitabine and ACH-126,443.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2006 | 5 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Alexion Pharmaceuticals, Inc. (7) · Thomas Jefferson University (1) · Pharmasset (1) · Incyte Corporation (1)
Studies
Open first, then newest update. How each study uses dexelvucitabine is read from its arms, and is right about nine times in ten.
Testing it · 10
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00350272Written as Elvucitabine
- Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V MutationCompletedPhase 1/2Alexion Pharmaceuticals, Inc.NCT00312039Written as Elvucitabine
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine TreatmentCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00675844Written as Elvucitabine
- Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014ACompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00380159Written as Elvucitabine
- Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus InfectionCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00034359Written as ACH-126,443
- Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIsTerminatedPhase 2Incyte CorporationNCT00300573Written as Dexelvucitabine
- Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.TerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT00040157Written as ACH126-443 (Beta-L-Fd4C)
- Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.TerminatedNot applicableAlexion Pharmaceuticals, Inc.NCT00037622Written as ACH-126, 443 (beta-L-Fd4C)
- Safety Study of Elvucitabine in HIV-1 SubjectsCompletedPhase 2Thomas Jefferson UniversityNCT00405249Written as elvucitabine
- A Study of DPC 817 in HIV-Infected MalesCompletedPhase 1PharmassetNCT00040274Written as DPC 817
Codes
What other systems call dexelvucitabine · ClinicalTrials.gg INT003902
- MeSH (NLM) C099405dexelvucitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KU8SPJ271WDEXELVUCITABINEConfirmed FDA, NLM, Wikidata
- Wikidata Q5268320dexelvucitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76928DexelvucitabineOne source FDA
- DrugBank DB12470One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C099405 | dexelvucitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KU8SPJ271W | DEXELVUCITABINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5268320 | dexelvucitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76928 | Dexelvucitabine | One source FDA |
| DrugBank | DB12470 | — | One source Wikidata |
Also registered as elvucitabine (UNII M09BUF90C0).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.